Corbus Pharmaceuticals Holdings (CRBP) Net Income (2013 - 2025)
Corbus Pharmaceuticals Holdings (CRBP) posted quarterly Net Income of -$24.4 million for Q3 2025, down 34.86% year-over-year from -$37.5 million in Q3 2024, and down 27.49% quarter-over-quarter from -$19.2 million in Q2 2025.
Corbus Pharmaceuticals Holdings (CRBP) Net Income (2013 - 2025) Analysis & Trends
Corbus Pharmaceuticals Holdings' Net Income history runs 13 years deep, the most recent figure standing at -$24.4 million for Q3 2025.
- In Q3 2025, Net Income fell 34.86% year-over-year to -$24.4 million; the TTM figure through Dec 2025 stood at -$66.4 million (down 3.31% YoY), while the FY2024 annual figure was -$51.5 million, up 63.19% from the prior year.
- Net Income for Q3 2025 stood at -$24.4 million, down from -$19.2 million in the prior quarter.
- The five-year high for Net Income was -$9.2 million in Q1 2022, with the low at -$54.0 million in Q2 2021.
- The 5-year median for Net Income is -$19.2 million (2022), against an average of -$23.8 million.
- The sharpest annual moves came in 2022 and 2025: Net Income jumped 82.22% in 2022, then plunged 118.07% in 2025.
- Corbus Pharmaceuticals Holdings' Net Income stood at -$10.4 million in 2021, then slipped by 19.68% to -$12.5 million in 2022, then increased by 14.11% to -$10.7 million in 2023, then slipped by 16.86% to -$12.5 million in 2024, then tumbled by 94.82% to -$24.4 million in 2025.
- Business Quant data shows CRBP's Net Income at -$24.4 million in Q3 2025, -$19.2 million in Q2 2025, and -$22.8 million in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -355.03 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Corbus Pharmaceuticals Holdings | 127.63 Mn | -35.64 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -24.42 Mn |
| Jun 30, 2025 | -19.15 Mn |
| Mar 31, 2025 | -22.82 Mn |
| Dec 31, 2024 | -12.53 Mn |
| Sep 30, 2024 | -18.11 Mn |
| Jun 30, 2024 | -23.16 Mn |
| Mar 31, 2024 | -10.46 Mn |
| Dec 31, 2023 | -10.73 Mn |
| Sep 30, 2023 | -30.31 Mn |
| Jun 30, 2023 | -28.96 Mn |
| Mar 31, 2023 | -18.23 Mn |
| Dec 31, 2022 | -12.49 Mn |
| Sep 30, 2022 | -19.16 Mn |
| Jun 30, 2022 | -23.16 Mn |
| Mar 31, 2022 | -9.20 Mn |
| Dec 31, 2021 | -10.43 Mn |
| Sep 30, 2021 | -52.68 Mn |
| Jun 30, 2021 | -53.96 Mn |
| Mar 31, 2021 | -51.75 Mn |
| Dec 31, 2020 | -21.48 Mn |